Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cocaine Use Disorder and Cortical Dopamine

NCT03349606
Conditions
Cocaine Dependence
Interventions
d-amphetamine, [C-11]FLB 457
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Cognitive Impairments, RRSO
Interventions
lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Active Cocaine Users
Interventions
Cocaine, Sustained Release d-Amphetamine
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
21 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Withdrawn Not applicable Interventional Accepts healthy volunteers

E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

NCT01986764
Conditions
Planned RRSO
Interventions
Lisdexamfetamine, Estradiol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 48 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Targeting Anhedonia in Cocaine Use Disorder

NCT02773212
Conditions
Cocaine-Related Disorders, Anhedonia
Interventions
d-amphetamine, Contingency management, Placebo (for d-amphetamine)
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cocaine-Related Disorders
Interventions
Dextroamphetamine, D-amphetamine, placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Houston, Texas
Conditions
Post Traumatic Stress Disorder
Interventions
3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy
Drug · Behavioral
Lead sponsor
Stephen Robert Marder
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Completed Early Phase 1 Interventional

Brain Mechanisms in Young Adults

NCT03606473
Conditions
Cocaine-Related Disorders
Interventions
d-amphetamine, [C-11]NPA
Drug · Radiation
Lead sponsor
Gale Richardson
Other
Eligibility
25 Years to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of D-amphetamine on Reward Functioning

NCT03369015
Conditions
Anhedonia
Interventions
10 mg d-amphetamine, 20mg d-amphetamine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 35 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
ADHD, Narcolepsy
Interventions
ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo
Drug
Lead sponsor
Vallon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Cocaine Use Disorder
Interventions
Baseline [C-11]NPA PET Scan, d-amphetamine, Post-amphetamine [C-11]NPA PET Scan
Radiation · Drug
Lead sponsor
Rajesh Narendran
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers

PET Imaging of Dopamine in Healthy Study Participants

NCT00062946
Conditions
Healthy
Interventions
(18F)fallypride
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

NCT03103750
Conditions
ADHD
Interventions
Magnetic Resonance Imaging (MRI), PHNO, calcitriol, Placebo oral capsule, high-resolution research tomography, Dextro Amphetamine
Procedure · Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-amphetamine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg, SHP465 25mg
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Miami, Florida • Las Vegas, Nevada • Houston, Texas
Conditions
Marijuana Abuse
Interventions
THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Differential Responses to Drugs and Sweet Tastes

NCT03810703
Conditions
Bipolar II Disorder
Interventions
Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 19 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Orlando, Florida • Evansville, Indiana + 5 more
Completed Phase 2 Interventional Results available

Studying Amphetamine Withdrawal in Humans

NCT01215929
Conditions
Methamphetamine Dependence
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Methamphetamine Addiction
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

Decision Making Study in Young and Middle-Aged Adults: Part II

NCT03512171
Conditions
Healthy Adults
Interventions
Dextroamphetamine, Placebo, [18F]Fallypride, [18F]-FE-PE2I
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University
Other
Eligibility
20 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee